We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Preliminary Clinical Trial Demonstrates Feasibility of Treating Multiple Myeloma with the Patient's Own Marrow-Infiltrating Lymphocytes

By LabMedica International staff writers
Posted on 01 Jun 2015
Results of a small clinical trial support the feasibility of using a multiple myeloma patient's marrow-infiltrating lymphocytes (MILs) as the basis for adoptive T cell therapy (ACT).

Investigators at Johns Hopkins University (Baltimore, MD, USA) hypothesized that MIL-based ACT in multiple myeloma could impart greater anti-tumor immunity in that they are obtained from the tumor microenvironment. More...


They discussed results from the first MILs ACT multiple myeloma clinical trial in the May 20, 2015, online edition of the journal Science Translational Medicine. For this study 22 patients with either newly diagnosed or relapsed disease had their MILs harvested, activated, and expanded with anti-CD3/CD28 beads plus interleukin-2, and subsequently re-infused on the third day following the standard regimen of high dose chemotherapy and stem cell transplant therapy.

Results revealed that seven patients experienced at least 90% reduction in tumor cell volume and survived, on average, 25.1 months without cancer progression. The remaining 15 patients had an average of 11.8 progression-free months following MILs therapy. Overall survival was 31.5 months for those with less than 90% disease reduction, while follow-up time is currently more than six years for those with a better response. None of the participants exhibited serious side effects from the MILs therapy.

"What we learned in this small trial is that large numbers of activated MILs can selectively target and kill myeloma cells," said senior author Dr. Ivan Borrello, professor of oncology at Johns Hopkins University. "Several US cancer centers have conducted similar experimental treatments, known as adoptive T cell therapy, but the Johns Hopkins team is apparently the only one to use MILs. Other types of tumor-infiltrating cells can be used, but they are usually less plentiful in patients' tumors and may not grow as well outside the body."

Related Links:

Johns Hopkins University



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.